Chinook Therapeutics is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems.
Drug development in kidney diseases is experiencing a resurgence due to greater understanding of disease biology, utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
May 16, 2023
Chinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney Disease
May 9, 2023
Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates
May 5, 2023
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 16, 2023 at 8:15 AM EDT
Chinook’s Discussion of Data Presented at 60th ERA Congress
May 10, 2023 at 2:20 PM EDT
Bank of America Securities Healthcare Conference 2023